Co-Diagnostics, Inc. (NASDAQ:CODX) Short Interest Update

Co-Diagnostics, Inc. (NASDAQ:CODX) saw a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 193,700 shares, a decline of 16.7% from the February 13th total of 232,600 shares. Based on an average daily trading volume, of 207,200 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.6% of the company’s shares are short sold.

Co-Diagnostics Price Performance

Shares of CODX stock opened at $0.47 on Thursday. The stock has a market cap of $15.15 million, a PE ratio of -0.34 and a beta of 1.29. The stock has a 50-day moving average of $0.66 and a 200-day moving average of $0.93. Co-Diagnostics has a one year low of $0.43 and a one year high of $2.23.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Jane Street Group LLC bought a new position in shares of Co-Diagnostics during the third quarter worth $55,000. Thompson Davis & CO. Inc. raised its stake in Co-Diagnostics by 37.8% during the 4th quarter. Thompson Davis & CO. Inc. now owns 57,200 shares of the company’s stock worth $43,000 after buying an additional 15,700 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in Co-Diagnostics by 7.5% during the fourth quarter. Geode Capital Management LLC now owns 345,511 shares of the company’s stock worth $259,000 after acquiring an additional 24,236 shares in the last quarter. Institutional investors and hedge funds own 14.99% of the company’s stock.

About Co-Diagnostics

Co-Diagnostics, Inc, a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting.